Product image of Jansitin (Sitagliptin) supplied by GNH India

Jansitin

Active Ingredient:
Sitagliptin
Origin:
EU

Jansitin (Sitagliptin)

Sitagliptin, the active ingredient in Jansitin, is a DPP-4 inhibitor presented as a tablet for oral use. It helps improve glycemic control in adults with type 2 diabetes mellitus.

GNH India supplies Jansitin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is indicated for the management of type 2 diabetes mellitus, acting on the incretin pathway to improve glucose regulation.

  • Type 2 diabetes mellitus (monotherapy): improves fasting and post‑prandial blood glucose levels when used with diet and exercise.
  • Type 2 diabetes mellitus (combination therapy): used together with metformin or other oral antidiabetics to achieve target HbA1c.
  • Adults with inadequate glycemic control on existing therapy: provides an additional mechanism to lower glucose without causing weight gain.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, resulting in lowered blood glucose concentrations.

Side Effects

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory tract infection.
  • Headache: transient mild to moderate pain.
  • Upper respiratory infection: cough, sore throat.
  • Nausea: occasional stomach upset.
  • Diarrhea: loose stools.
  • Abdominal pain: mild discomfort.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring medical attention.
  • Severe allergic reactions: rash, angioedema, anaphylaxis.
  • Joint pain: unexplained arthralgia.
  • Bullous pemphigoid: rare skin blistering disorder.
  • Hepatic injury: elevated liver enzymes.
  • Severe hypoglycemia: when combined with insulin or sulfonylureas.

Precautions & Warnings

Before prescribing Jansitin, clinicians should consider several safety aspects.

  • Renal impairment: adjust dose or avoid in severe renal dysfunction.
  • Hepatic impairment: use with caution in patients with liver disease.
  • History of pancreatitis: monitor closely for recurrent episodes.
  • Elderly patients: observe for hypoglycemia when used with insulin or sulfonylureas.
  • Pregnancy and lactation: safety not established; weigh benefits against risks.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Sitagliptin may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

  • Insulin: increased risk of hypoglycemia.
  • Sulfonylureas (e.g., glipizide): heightened hypoglycemia potential.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin exposure.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce sitagliptin effectiveness.
  • Diuretics: can affect glucose control, monitor blood sugar.
  • Warfarin: monitor INR as sitagliptin may alter anticoagulant response.

Frequently Asked Questions

Jansitin contains sitagliptin, a DPP‑4 inhibitor prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a regimen that includes diet, exercise, and possibly other antidiabetic agents.

Sitagliptin blocks the DPP‑4 enzyme, which normally degrades incretin hormones. By preserving incretins such as GLP‑1 and GIP, the drug enhances insulin secretion and reduces glucagon release in a glucose‑dependent manner, helping to lower blood sugar levels.

The specific dose of Jansitin is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the dose prescribed by their clinician.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Jansitin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycemia because its insulin‑stimulating effect is glucose‑dependent. Unlike metformin, it does not affect gastrointestinal absorption and is generally weight‑neutral. It offers an alternative mechanism for patients who cannot tolerate other agents.

Jansitin tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Jansitin is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless otherwise instructed.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or difficulty breathing.

Jansitin is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. It should also be avoided in individuals with severe renal impairment unless dose adjustments are made, and in those with a history of pancreatitis without careful monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT